Loading...
Oncolytics Biotech Inc.
ONC.TO•TSX
Healthcare
Biotechnology
CA$0.87
CA$0.05(6.10%)
Oncolytics Biotech Inc. (ONC.TO) Financial Performance & Statements
Review Oncolytics Biotech Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
0.00%
Net Income Growth
0.00%
Operating Cash Flow Growth
5.21%
↑ 5.21%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-225.21%
↓ 225.21%
ROIC
-259.13%
↓ 259.13%
Oncolytics Biotech Inc. (ONC.TO) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Oncolytics Biotech Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $98000.00 | $123000.00 |
| Gross Profit | $0.00 | $0.00 | -$98000.00 | -$123000.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $4.55M | $6.79M | $4.56M | $5.74M |
| SG&A Expenses | $3.46M | $3.10M | $3.36M | $2.86M |
| Operating Expenses | $8.44M | $9.90M | $7.92M | $8.60M |
| Total Costs & Expenses | $8.44M | $9.90M | $7.92M | $8.73M |
| Interest Income | $152000.00 | $261000.00 | $340000.00 | $446000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $98000.00 | $105000.00 | $0.00 | $123000.00 |
| EBITDA | -$8.34M | -$9.79M | -$7.92M | -$8.60M |
| EBITDA Ratio | ||||
| Operating Income | $0.00 | -$9.90M | -$7.92M | -$8.73M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$7.99M | $368000.00 | $759000.00 | $1.83M |
| Income Before Tax | -$7.99M | -$9.53M | -$7.16M | -$6.89M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $23000.00 | $12000.00 | $95000.00 | $79724.00 |
| Net Income | -$8.02M | -$9.54M | -$7.26M | -$6.89M |
| Net Income Ratio | ||||
| EPS | -$0.11 | -$0.13 | -$0.10 | -$0.09 |
| Diluted EPS | -$0.11 | -$0.13 | -$0.10 | -$0.09 |
| Weighted Avg Shares Outstanding | $76.09M | $76.09M | $76.09M | $75.24M |
| Weighted Avg Shares Outstanding (Diluted) | $76.09M | $76.09M | $76.09M | $75.24M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan